This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01209/identifier/chebi/
n6http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01209/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01209/identifier/kegg-compound/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01209/identifier/kegg-drug/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01209/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01209
rdf:type
n3:Drug
n3:description
Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.
n3:group
approved
n3:halfLife
Elimination half-life following intramuscular administration averages 2.2 hours. Elimination half-life following a 5mg intravenous dose averages 1.7 to 2.6 hours (range 0.6 to 4.4 hours) while a 10mg dose averages 2.4 to 2.6 hours (range 1.2 to 7.4 hours). In patients with hepatic cirrhosis, the half-life is increased by 30 to 50%.
n3:indication
Indicated in the treatment of moderate to severe pain.
owl:sameAs
n10:DB01209 n11:DB01209
dcterms:title
Dezocine
adms:identifier
n8:PA164746059 n12:C08010 n13:D00838 n14:4474 n17:DB01209
n3:mechanismOfAction
Dezocine is a opioid analgesic drug of mixed agonist-antagonist type. It binds with stereospecific receptors at many sites within the central nervous system (CNS) to alter processes affecting both the perception of pain and the emotional response to pain. At least 2 of these types of receptors (mu and kappa) mediate analgesia. Mu receptors are widely distributed throughout the CNS, especially in the limbic system (frontal cortex, temporal cortex, amygdala, and hippocampus), thalamus, striatum, hypothalamus, and midbrain as well as laminae I, II, IV, and V of the dorsal horn in the spinal cord. Kappa receptors are localized primarily in the spinal cord and in the cerebral cortex.
n3:synonym
Dezocinum Dezocina (-)-13beta-amino-5,6,7,8,9,10,11alpha,12-Octahydro-5alpha-methyl-5,11-methanobenzocyclodecen-3-ol
n3:toxicity
Symptoms of overdose include cold and clammy skin, confusion, nervousness, or severe restlessness, convulsions (seizures), severe dizziness, severe drowsiness, low blood pressure, pinpoint pupils of eyes, slow heartbeat, slow or troubled breathing and severe weakness.
n5:hasConcept
n6:M0056650
n3:IUPAC-Name
n4:271B5632-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5638-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5637-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5634-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5635-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5636-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5630-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B562E-363D-11E5-9242-09173F13E4C5 n4:271B5648-363D-11E5-9242-09173F13E4C5 n4:271B5631-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B562F-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:N02AX03
n3:H-Bond-Acceptor-Count
n4:271B563E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B563F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5639-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B563A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B563C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B563B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B563D-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid and complete following intramuscular administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53648-55-8
n3:category
n3:Bioavailability
n4:271B5644-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5646-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5647-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5643-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5642-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5645-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5633-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5640-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5641-363D-11E5-9242-09173F13E4C5